Psyence BioMed to Invest Up to $5 Million in PsyLabs for U.S. Ibogaine Program

Psyence BioMed Ltd. (PBM) said on September 23, 2026, it agreed to invest up to $5 million in cash in Psyence Labs Ltd. and enter a value-matched share exchange to fund its planned U.S. ibogaine program. The company disclosed the agreement on Wednesday, September 23, 2026. Further financial terms of the share exchange were not disclosed. Psyence BioMed is a life sciences company focused on psychedelic-based therapeutics. The investment targets PsyLabs' ibogaine development efforts in the United States.